References
- U.S. National Library of Medicine. What is pharmacogenomics? Bethesda (MD); 2019 Oct 1 [accessed 2019 Oct 3]. https://ghr.nlm.nih.gov/primer/genomicresearch/pharmacogenomics.
- Mahajan PB. Will pharmacogenomics take the pain out of pain medication? J Pharmacogenomics Pharmacoproteomics. 2014;6:e142. doi:10.4172/21530645.1000e142.
- Rollason V, Samer C, Piguet V, Dayer P, Desmeules J. Pharmacogenetics of analgesics: toward the individualization of prescription. Pharmacogenomics. 2008;9(7):905–933. doi:10.2217/14622416.9.7.905.
- Weinshilboum RM, Wang L. Pharmacogenomics: precision medicine and drug response. Mayo Clin Proc. 2017;92(11):1711–1722. doi:10.1016/j.mayocp.2017.09.001.
- Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–350. doi:10.1038/nature15817.
- Ting S, Schug S. The pharmacogenomics of pain management: prospects for personalized medicine. J Pain Res. 2016;9:49–56. doi:10.2147/JPR.S55595.
- Lebe M, Hasenbring MI, Schmieder K, Jetschke K, Harders A, Epplen JT, Hoffjan S, Kötting J. Association of serotonin-1A and -2A receptor promoter polymorphisms with depressive symptoms, functional recovery, and pain in patients 6 months after lumbar disc surgery. Pain. 2013;154(3):377–384. doi:10.1016/j.pain.2012.11.017.
- Direct to Consumer Tests [Internet]. White Oak (MD): U.S. FDA; 2018 Nov 1 [accessed 2019 Oct 7]. https://www.fda.gov/medical-devices/vitro-diagnostics/direct-consumer-tests.
- OneOme – Making prescriptions personal through pharmacogenomic testing [Internet]. Rochester (MN): Oneome; 2019 [accessed 2019 Oct 2]. https://www.oneome.com/.
- FDA Table of Pharmacogenomic Biomarkers in Drug Labeling [Internet]. White Oak (MD): US FDA; 2019 Sept 3 [accessed 2019 Oct 7]. https://www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling.
- Bank PC, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, Relling MV, Guchelaar H. Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther. 2018;103(4):599–618. doi:10.1002/cpt.762.
- Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, Altman RB, Klein TE. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–417. doi:10.1038/clpt.2012.96.
- Cpicpgx.org. [Internet]. Stanford (CA): Clinical Pharmacogenetics Implementation Consortium; 2019 [accessed 2019 Oct 2]. https://cpicpgx.org/.
- PharmGKB.org. [Internet]. Stanford (CA): PharmGKB; 2019 [accessed 2019 Oct 2]. https://www.pharmgkb.org/.
- Agarwal D, Udoji MA, Trescot A. Genetic testing for opioid pain management: a primer. Pain Ther. 2017;6(1):93–105. doi:10.1007/s40122-017-0069-2.
- FDA Drug Safety Communication: FDA restricts use of prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women [Internet]. White Oak (MD): U.S. FDA; 2018 Mar 8 [accessed 2019 Oct 7]. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-restricts-use-prescription-codeine-pain-and-cough-medicines-and.
- Ciszkowski C, Madadi P, Phillips MS, Lauwers AE, Koren G. Codeine, ultrarapid-metabolism genotype, and postoperative death. N Engl J Med. 2009;361(8):827–828. doi:10.1056/NEJMc0904266.
- Gasche Y, Daali Y, Fathi M, Chiappe A, Cottini S, Dayer P, Desmeules J. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351(27):2827–2831. doi:10.1056/NEJMoa041888.
- Rakvag TT, Klepstad P, Baar C, Kvam TM, Dale O, Kaasa S, Krokan HE, Skorpen F. The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005;116:73–78. doi:10.1016/j.pain.2005.03.032.
- Zubieta JK, Heitzeg MM, Smith YR, Bueller JA, Xu K, Xu Y, Koeppe RA, Stohler CS, Goldman D. COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science. 2003;299(5610):1240–1243. doi:10.1126/science.1078546.
- Gong XD, Wang JY, Liu F, Yuan HH, Zhang WY, Guo YH, Jiang B. Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain. Asian Pac J Cancer Prev. 2013;14(5):2937–2943. doi:10.7314/APJCP.2013.14.5.2937.
- Klepstad P, Rakvag TT, Kaasa S, Holthe M, Dale O, Borchgrevink PC, Baar C, Vikan T, Krokan HE, Skorpen F. The 118A > G polymorphism in the human μ-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand. 2004;48(10):1232–1239. doi:10.1111/j.1399-6576.2004.00517.x.
- FDA News Release: FDA issues warning letter to genomics lab for illegally marketing genetic test that claims to predict patients’ responses to specific medications [Internet]. White Oak (MD): U.S. FDA; updated 2019 Apr 4; [accessed 2019 Oct 2]. https://www.fda.gov/news-events/press-announcements/fda-issues-warning-letter-genomics-lab-illegally-marketing-genetic-test-claims-predict-patients.